Towa Pharmaceutical (4553.T) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

4553.T · Stock Price

JPY 3,910+1,256 (+47.32%)

Market Cap: $1.2B

Historical price data

Overview

Towa Pharmaceutical's mission is to ensure a stable supply of high-quality, affordable generic medicines to the Japanese healthcare system. The company has achieved a leading market position through its integrated development and manufacturing platform, becoming one of Japan's most valuable pharmaceutical enterprises. Its strategy centers on deepening its domestic market penetration, expanding into complex generics and biosimilars, and pursuing selective international opportunities to drive sustainable growth.

Broad Generic PortfolioCardiovascularCNSMetabolicOncologyInfectious Disease

Technology Platform

A fully integrated platform for generic drug development and manufacturing, encompassing in-house API synthesis, advanced formulation science, bioequivalence testing, and high-quality GMP production.

Pipeline

1

1 drug in pipeline

Drug	Indication	Stage	Watch
Bromocriptine Mesilate + Placebos	Familial Alzheimer Disease (FAD)	Phase 1/2

Funding History

1

IPOUndisclosedUndisclosedMar 15, 2002

Opportunities

The primary opportunity is the continued high-level of government-mandated generic drug penetration in Japan, coupled with a steady stream of blockbuster drug patent expirations.

Further growth lies in capturing higher-margin segments like complex generics and biosimilars, and potential selective international expansion.

Risk Factors

Key risks include ongoing government-mandated price cuts every two years, potential delays in regulatory approvals for pipeline products, increased competition in the generic market, and execution risks associated with moving into complex generics and biosimilars.

Competitive Landscape

Towa competes with domestic generic leaders like Sawai Pharmaceutical and Teva Takeda Pharma, as well as global generics firms. Its competitive advantages are full vertical integration, deep PMDA regulatory expertise, a trusted brand for quality, and a dominant domestic distribution network.

More companies in Small Molecule Drugs →More companies in Japan →